SUMMARY One hundred and three consecutive infants < 32 weeks' gestation with recurrent apnoea of immaturity were reviewed, and survival was assessed and related to timing of treatment. The sickest infants were treated after between one and three episodes of apnoea with bradycardia, and mortality was 70%. Of those in whom treatment was postponed because apnoea was considered mild, 34% subsequently required mechanical ventilation, and 23 % died. Among a small group of 20 survivors seen at ages 9-24 months, 4 (20 %) have major handicaps. The possible place for earlier treatment is discussed.
A controlled trial of theophylline and continuous positive airways pressure (CPAP) was undertaken for treating apnoea in preterm infants and is reported on page 761. Despite agreed criteria for treatment, therapy was often delayed for many hours or days and several eligible infants remained untreated because of reluctance to treat apparently mild apnoea with either agent. This paper reports the mortality of treated and untreated infants and considers the effect of delaying therapy. A group of 20 treated survivors was followed up to ascertain the incidence of handicap.
Method
Details of the controlled trial are reported in the previous paper (page 761), including definitions of recurrent apnoea.1 All admissions to the two neonatal units during the 27-month study were reviewed and the nurses' records of apnoeic attacks extracted from the notes. Medical notes and investigations were checked to exclude infants with secondary apnoea (as previously defined'). The time of starting treatment was noted and related to the time at which the infant fulfilled the trial entry criteria. Deaths up to age one year were recorded.
The 20 surviving infants from the controlled trial were seen (by R A K J) at ages 9 to 24 (median 12) months for full neurological examination, vision and hearing testing, and assessment using The design of the controlled trial allowed for infants failing to respond to one treatment being changed to the other. Unfortunately, the unexpectedly poor response to CPAP meant that most survivors from that group subsequently received theophylline; 9 survivors had received theophylline alone, 4 CPAP alone, and 7 both treatments. Comparison of outcome for the two treatments was thus not possible, and the results are given for the group as a whole.
A questionnaire (available from us) was devised by the clinical psychologist (D L) to assess behavioural problems at ages 9 to 12 months, and was given to 15 mothers (omitting 5 older children).
It was similar to one used in a large study of preschool children,4 with questions on feeding, sleeping, teething, general mood, and management difficulties. It was also given to 20 mothers of normal infants aged 7 to 10 months (10 boys, 10 girls), picked at random from local child health clinic attenders. Infants were placed in one of 3 categories: slight difficulties or none, moderate difficulties, and pronounced difficulties.
In addition to the detailed assessment on these 20 infants, babies not entered into the trial were followed routinely in the outpatient departments of the two hospitals or by their referring paediatricians, and details were available in all but 6 survivors. Of the total of 68 infants surviving recurrent apnoea, 16 (24 %) are known to have major handicaps after 1 to 2 years' follow-up. Of the 30 untreated survivors, 6 are handicapped.
Discussion
Despite strict criteria for treating recurrent apnoea, delay was common because of reluctance of nursing or junior medical staff to start treatments they considered hazardous. The infants treated the earliest had the worst prognosis, but their apnoea was often very severe needing immediate intubation and IPPV. Of the 71 in whom treatment was delayed, 34% later required IPPV and 23 % died, so the condition was hardly benign. The fact that all but 11 of 103 infants had further apnoea after fulfilling the initial criteria suggests that this was a reasonable basis for treatment. Of those treated after delay with either theophylline or CPAP, both established forms of therapy, 17 of 33 responded poorly requiring IPPV, compared with only 3 of 11 infants given theophylline or CPAP promptly.
The occurrence of major handicap in 4 of 20 survivors all of whom had required IPPV is comparable with the 25 % reported by Stewart et 
